Tempus AI stock slips premarket after 7.5% jump as JPM Healthcare Conference nears

Tempus AI stock slips premarket after 7.5% jump as JPM Healthcare Conference nears

NEW YORK, Jan 7, 2026, 07:47 ET — Premarket

  • Tempus AI shares down about 1% in premarket after a 7.5% rise on Tuesday
  • Company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12
  • SEC filing shows director Jennifer Doudna sold 1,250 shares under a 10b5-1 plan

Tempus AI, Inc shares were down about 1% in premarket trading on Wednesday, easing after the Nasdaq-listed health-tech stock jumped 7.5% in the previous session. The shares last traded around $68.85, after closing at $69.54 on Tuesday.

The pullback comes as investors position for Tempus’ appearance at the annual J.P. Morgan Healthcare Conference, a closely watched investor meeting that often sets the tone for healthcare stocks early in the year.

Tempus said its founder and CEO Eric Lefkofsky will deliver a presentation and take questions on Jan. 12, with a live webcast available to investors.

Tempus has not confirmed its next earnings date, but market schedules estimate the company will report around Feb. 23. Any color on testing demand, reimbursement and spending at the conference could shape expectations heading into that report.

A regulatory filing showed director Jennifer Doudna sold 1,250 shares at $60.17 on Jan. 2 under a Rule 10b5-1 plan, a pre-arranged trading program that sets conditions for future stock sales. She held 22,702 shares after the sale, the filing showed.

Tempus last reported third-quarter revenue up 84.7% to $334.2 million and adjusted EBITDA of $1.5 million. It posted a net loss of $80.0 million and ended the quarter with $764.3 million in cash and marketable securities; Lefkofsky called positive adjusted EBITDA “an important milestone.” SEC

Broader markets were cautious early Wednesday, with U.S. stock futures edging lower after a rally that pushed the S&P 500 and Dow to record closes, while investors awaited labor market data due later in the day.

But Tempus remains a high-beta healthcare name, and the stock can turn quickly if management offers little new at conferences or if spending rises faster than revenue growth. Any disappointment on margins or demand could test the durability of Tuesday’s sharp move.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Kodiak Gas Services

NYSE:KGS • Energy infrastructure 88/100 • ★★★★☆
#2 STRONG BUY

Neurocrine Biosciences

NASDAQ:NBIX • Healthcare 87/100 • ★★★★☆
#3 STRONG BUY

Alphabet Class A

NASDAQ:GOOGL • Communication services 85/100 • ★★★★☆
#4 BUY ON WEAKNESS

Applied Materials

NASDAQ:AMAT • Semiconductor equipment 84/100 • ★★★★☆
#5 ACCUMULATE

JPMorgan Chase

NYSE:JPM • Financials 80/100 • ★★★★☆
View full portfolio
Editorial model selection. Not personalised advice.
Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results
Previous Story

Prudential plc stock slips as $1.2bn buyback kicks off; investors eye March results

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next
Next Story

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next